Zentalis Pharmaceuticals, Inc. $ZNTL Shares Sold by Almitas Capital LLC

Impact · against what's priced in

Almitas Capital's decision to liquidate 71.4% of its Zentalis Pharmaceuticals position suggests a shift in institutional confidence. This significant divestment creates negative pressure on the stock's momentum.

ZNTL−0.30

No priced-in read yet

In context

Almitas Capital LLC reduced its stake in Zentalis by 71.4%, selling 1,141,944 shares, which typically indicates a bearish outlook from a major institutional holder.

Read from the article alone

• biotech
• pharmaceuticals
• 13f
• ZNTL
• institutional investing
• portfolio rebalancing
• sec filing

Search tags